by barry101 | Oct 19, 2021 | Press Releases
– First-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers and establish maximum tolerated dose expected to commence in 4th Quarter 2021 — Based on previously announced preclinical data demonstrating its...
by barry101 | Oct 18, 2021 | Press Releases
– Preliminary data from two cohorts evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases currently demonstrate 80% clinical activity, defined as stable disease and/or better- Patient enrollment and dosing ongoing; no dose-limiting...
by barry101 | Sep 27, 2021 | Press Releases
– Live webcast presentation on Monday, September 27th at 8:40 AM ETHOUSTON, Sept. 27, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
by barry101 | Sep 17, 2021 | Press Releases
– Live webcast presentation on Monday, September 20th at 4:35 PM ET HOUSTON, Sept. 17, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
by barry101 | Sep 8, 2021 | Press Releases
HOUSTON, Sept. 8, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp,...
by barry101 | Aug 12, 2021 | Press Releases
– Continued execution of multiple ongoing clinical studies for the treatment of highly resistant tumors and viruses — Key clinical and regulatory milestones throughout next 18 months including topline results from the ongoing Phase 1/2 study of Annamycin...
